Entropy Technologies LP Buys New Position in DexCom, Inc. (NASDAQ:DXCM)

Entropy Technologies LP bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 51,914 shares of the medical device company’s stock, valued at approximately $3,480,000.

Several other institutional investors have also modified their holdings of DXCM. Taylor Frigon Capital Management LLC boosted its position in shares of DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the period. National Pension Service boosted its holdings in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares during the period. Intact Investment Management Inc. purchased a new stake in shares of DexCom in the 3rd quarter valued at approximately $650,000. Waters Parkerson & CO. LLC boosted its stake in DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after purchasing an additional 10,892 shares during the period. Finally, Legal & General Group Plc boosted its stake in DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on DXCM. Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Robert W. Baird raised their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Stifel Nicolaus upped their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Finally, BTIG Research dropped their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

DexCom Stock Up 0.5 %

Shares of DXCM stock opened at $70.31 on Tuesday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market cap of $27.46 billion, a PE ratio of 42.10, a price-to-earnings-growth ratio of 2.15 and a beta of 1.17. The stock has a 50 day moving average of $69.66 and a 200-day moving average of $93.10.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.